NasdaqGS:FDMTBiotechs
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative
4D Molecular Therapeutics (FDMT) closed out FY 2025 with Q4 revenue of US$85.1 million and basic EPS of US$0.30, a sharp contrast to the prior quarter when revenue was US$0.09 million and EPS was a loss of US$1.01. Over the past few quarters, revenue has moved from US$0.001 million in Q4 2024 to US$0.09 million in Q3 2025 and then to US$85.1 million in Q4 2025, while EPS has shifted from a loss of US$0.89 to a loss of US$1.01 before turning to a positive US$0.30. This sets up a story where...